Pharmacokinetics and antiviral activity of a novel isonucleoside, BMS-181165, against simian varicella virus infection in African green monkeys.
A novel nucleoside analog BMS-181165 with potent activity against varicella-zoster virus was tested for efficacy in a simian varicella virus infection in African green monkeys. BMS-181165 was effective in preventing the development of a rash, decreasing the development of viremia and preventing death in infected monkeys when administered orally at 4, 16 or 64 mg/kg/day. The compound is well orally absorbed in monkeys, between 44 to 50% oral bioavailability, and may prove of value in therapy of varicella-zoster infections in humans.
Soike
K F
KF
Tulane Regional Primate Research Center, Covington, LA 70433.
Huang
J L
JL
Russell
J W
JW
Whiterock
V J
VJ
Sundeen
J E
JE
Stratton
L W
LW
Clark
J M
JM
D000284:Administration, Oral; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D001682:Biological Availability; D002522:Chlorocebus aethiops; D004195:Disease Models, Animal; D006566:Herpesviridae Infections / Q000150:complications / Q000517:prevention & control*; D006568:Herpesvirus 1, Cercopithecine; D016896:Treatment Outcome; D014529:Uridine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D014766:Viremia / Q000517:prevention & control
D000998:Antiviral Agents; C081111:BMS 181165; D014529:Uridine